#JunckerPlan supports chronic disease prevention in #Finland

| January 22, 2019

The Investment Plan for Europe, or Juncker Plan, is backing a €20 million European Investment Bank (EIB) loan to Finnish company Nightingale Health. The company will use the financing to further develop its blood analysis technology, which facilitates the detection and prevention of chronic diseases.

Jobs, Growth, Investment and Competitiveness Vice President Jyrki Katainen, who attended the signature event in Helsinki, said: “Europe invests heavily in education and science as we believe that putting a strategic effort into these areas can reap huge benefits. This commitment has resulted in Europe’s position today as a world leader in cutting edge medical research. We are delighted that the Investment Plan for Europe is fostering the development of Nightingale’s technology which has the potential to add significant value to European healthcare.”

Nightingale’s innovative blood analysis technology can detect early signs of chronic diseases, improving for example the assessment of a person’s future risk of developing heart disease or type 2 diabetes. A press release is available here. As of December 2018, the European Fund for Strategic Investments (EFSI), at the heart of the Juncker Plan, had already mobilized €371.2 billion of additional investments, including €7.8bn in Finland.


Facebook comments

Tags: , , ,

Category: A Frontpage, EU, European Commission, Finland

Comments are closed.

Left Menu Icon